Esperion Therapeutics (NASDAQ:ESPR) Shares Up 3.3%
Esperion Therapeutics (NASDAQ:ESPR) Shares Up 3.3%
Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) shot up 3.3% during trading on Tuesday . The stock traded as high as $6.91 and last traded at $6.91. 115,696 shares traded hands during mid-day trading, a decline of 92% from the average session volume of 1,422,240 shares. The stock had previously closed at $6.69.
Esperion Treateutics，Inc.(纳斯达克代码：ESPR-GET评级)的股价在周二的交易中飙升了3.3%。该股最高交易价格为6.91美元，最后报6.91美元。午盘成交量为115,696股，较1,422,240股的平均成交量下降92%。该股此前收盘价为6.69美元。
Wall Street Analyst Weigh In
华尔街分析师也加入进来
Several brokerages have commented on ESPR. Morgan Stanley raised their price target on shares of Esperion Therapeutics from $7.00 to $9.00 and gave the company an "underweight" rating in a research report on Wednesday, November 2nd. StockNews.com raised shares of Esperion Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, November 3rd. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $11.20.
几家券商对ESPR发表了评论。11月2日，周三，摩根士丹利在一份研究报告中将Esperion治疗公司的股票目标价从7.00美元上调至9.00美元，并给予该公司“减持”评级。在11月3日星期四的一份研究报告中，StockNews.com将Esperion治疗公司的股票评级从“卖出”上调至“持有”。两名股票研究分析师对该股的评级为卖出，两名分析师给予该股持有评级，一名分析师对该股给予买入评级。根据MarketBeat.com的数据，该股目前的平均评级为持有，共识目标价为11.20美元。
Esperion Therapeutics Stock Performance
Esperion Treateutics股票表现
The company's 50 day moving average is $6.54 and its 200 day moving average is $6.98.
该公司的50日移动均线切入位在6.54美元，200日移动均线切入位在6.98美元。
Insider Buying and Selling at Esperion Therapeutics
Esperion Treateutics的内幕买卖
In other Esperion Therapeutics news, General Counsel Benjamin Looker sold 6,347 shares of Esperion Therapeutics stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $7.00, for a total value of $44,429.00. Following the transaction, the general counsel now directly owns 64,453 shares in the company, valued at $451,171. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 3.30% of the stock is currently owned by company insiders.
在其他Esperion治疗公司的消息中，总法律顾问Benjamin Looker在1月18日星期三的一笔交易中出售了6,347股Esperion治疗公司的股票。这些股票的平均价格为7.00美元，总价值为44429.00美元。交易完成后，总法律顾问现在直接拥有该公司64,453股，价值451,171美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可在以下网址获得美国证券交易委员会网站。3.30%的股份目前由公司内部人士持有。
Institutional Trading of Esperion Therapeutics
Esperion治疗药物的制度性交易
A number of institutional investors have recently added to or reduced their stakes in the stock. Wasatch Advisors Inc. boosted its holdings in Esperion Therapeutics by 27.6% during the first quarter. Wasatch Advisors Inc. now owns 8,147,380 shares of the biopharmaceutical company's stock worth $37,804,000 after buying an additional 1,761,117 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Esperion Therapeutics by 19.4% during the first quarter. Vanguard Group Inc. now owns 4,491,530 shares of the biopharmaceutical company's stock worth $20,841,000 after buying an additional 730,091 shares in the last quarter. Millennium Management LLC boosted its holdings in Esperion Therapeutics by 116.8% during the second quarter. Millennium Management LLC now owns 2,706,290 shares of the biopharmaceutical company's stock worth $17,212,000 after buying an additional 1,457,952 shares in the last quarter. Ikarian Capital LLC purchased a new stake in Esperion Therapeutics during the second quarter worth about $13,067,000. Finally, State Street Corp boosted its holdings in Esperion Therapeutics by 23.2% during the third quarter. State Street Corp now owns 1,533,148 shares of the biopharmaceutical company's stock worth $10,272,000 after buying an additional 288,609 shares in the last quarter. Hedge funds and other institutional investors own 85.87% of the company's stock.
一些机构投资者最近增持或减持了该股。Wasatch Advisors Inc.在第一季度将其在Esperion Treateutics的持股增加了27.6%。Wasatch Advisors Inc.现在持有这家生物制药公司8,147,380股票，价值37,804,000美元，上个季度又购买了1,761,117股票。先锋集团第一季度增持了Esperion Treateutics 19.4%的股份。先锋集团(Vanguard Group Inc.)现在持有这家生物制药公司4,491,530股股票，价值20,841,000美元，上季度又购买了730,091股。千禧管理有限责任公司在第二季度增持了116.8%的Esperion Treateutics股份。Millennium Management LLC现在拥有这家生物制药公司2,706,290股股票，价值17,211,000美元，上个季度又购买了1,457,952股。伊卡里安资本有限责任公司在第二季度购买了Esperion治疗公司的新股份，价值约13,067,000美元。最后，道富银行在第三季度增持了Esperion治疗公司23.2%的股份。道富集团目前持有这家生物制药公司1,533,148股股票，价值10,272,000美元，上一季度又购买了288,609股。对冲基金和其他机构投资者持有该公司85.87%的股票。
Esperion Therapeutics Company Profile
Esperion治疗公司简介
(Get Rating)
(获取评级)
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.
Esperion Treateutics，Inc.是一家制药公司，开发和销售治疗低密度脂蛋白胆固醇升高患者的药物。它的主要候选产品是用于治疗动脉粥样硬化性心血管疾病或杂合性家族性高胆固醇血症患者的NEXLETOL(苯培多酸)和NEXLIZET(苯培多酸和依折麦布)片剂。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Esperion Therapeutics (ESPR)
- Intuit Is About To Make a Move, But Which Way?
- 3 Late January Earnings Plays With Pop Potential
- Low-Priced Stocks Still Paying Dividends
- Why is the Chipotle Stock Price Surging This Week?
- Is the Northrop Grumman Selloff an Opportunity?
- 免费获取StockNews.com关于Esperion治疗(ESPR)的研究报告
- Intuit即将采取行动，但走哪条路呢？
- 1月下旬收益表现出流行音乐的潜力
- 低价股仍在派发股息
- 为什么Chipotle的股价本周飙升？
- 诺斯罗普·格鲁曼公司的抛售是一个机会吗？
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受Esperion治疗日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收Esperion Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。